Antibacterial Drug Development Market Pipeline Review 2017

Antibacterial Therapies Drug Development Pipeline Review 2017 report covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.

Inquire for Complete PDF Report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=945729

Description of Report:

Antibacterial Therapies Drug Development Pipeline Review H2 2017 report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the body’s immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future. Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.

Key Companies Analyzed In Report:
AAbera Bioscience AB, Akthelia Pharmaceuticals, Alvogen Korea, Anacor Pharmaceuticals, Archivel Farma S.L., AstraZeneca, Beech Tree Labs, BioDiem Ltd, BioLingus AG, Biomar Microbial Technologies, Bioversys AG, Celgene Corporation, Ceeutix Corporation, Chongqing Zhifei Biological Products, Crestone, Dafra Pharma International, Daiichi Sankyo Company, Demuris, Eisai, Eli Lilly and Company, Ensol Biosciences, EpiVax, FIT Biotech Oy, GangaGen, GlaxoSmithKline, Globeimmune, Hager Biosciences, Hsiri Therapeutics, Imaxio SA, Immunitor, ImmunoBiology, Inovio Pharmaceuticals, Johnson & Johnson, Lakewood-Amedex, Lipotek Pty, Matinas BioPharma Holdings, Microbion Corporation, Microbiotix, NEARMEDIC PLUS Ltd, Novartis AG, NovoBiotic Pharmaceuticals, Otsuka Holdings, QureTech Bio AB, Recce Pty Ltd, Rodos BioTarget GmbH

Key Questions Answered In report:
Which companies are the most active within the pipeline for antibacterial drugs? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area?

Get Discount On Report @ http://www.reportsnreports.com/contacts/discount.aspx?name=945729

Report helps to understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication. Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each. Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these. Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Major Table OF Content:

• Number of Products under Development for Tuberculosis 22
• Number of Products under Development for Tuberculosis - Comparative Analysis 23
• Number of Products under Development for Community Acquired Pneumonia 24
• Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25
• Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 26
• Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27
• Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 28
• Number of Products under Development for Pseudomonas aeruginosa Infections 29
• Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis 30
• Number of Products under Development for Klebsiella pneumoniae Infections 31
• Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis 32
• Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33
• Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis 34
• Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35
• Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36
• Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis 37
• Number of Products under Development by Companies, Tuberculosis 38
• Number of Products under Development by Companies, Community Acquired Pneumonia 41
• Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 42
• Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 44
• Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46

Buy Report: http://www.reportsnreports.com/contacts/requestsample.aspx?name=945729

About Us:
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Learn details of Global Antibacterial Therapies Drug Development Pipeline Review 2017.Report provide information on companies are the most active within the pipeline for antibacterial drugs and Antibacterial products in active development in the antibacterial drug market.

Ritesh Tiwari
2nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune – 411013.
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

This release was published on openPR.